EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Allogeneic hematopoietic cell transplantation is curative in CARMIL2 deficiency

Johannes Raedler iD, Florian Gothe iD, Thomas Magg iD, Philipp Peters iD, Karen Helene Bronken Martinsen iD, Ursula Holzer iD, Ayca Kiykim iD, Ayse Kalyoncu Ucar iD, Roshini S Abraham iD, Hemalatha G Rangarajan iD, Adeeb NaserEddin iD, Polina Stepensky iD und 16 weitere

Journal of Human Immunity · 07.09.2026 · 2 (5)

DOI: 10.70962/jhi.20250200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 29.07.2026. Verfasst von Johannes Raedler und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LMU Munich, French National Research Agency, Institut National de la Santé et de la Recherche Médicale.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biallelic loss-of-function variants in capping protein regulator and myosin 1 linker 2 (CARMIL2) cause a complex disorder of immune dysregulation hallmarked by susceptibility to infections, inflammatory bowel and skin disease, and Epstein-Barr virus–positive smooth muscle tumors (EBV+ SMTs). We report a multicenter retrospective study to evaluate hematopoietic cell transplantation (HCT) outcomes in CARMIL2-deficient patients. 17 patients underwent 19 HCTs, with a total follow-up of 768 mo and a median follow-up of 37 mo (range 1–195). Three patients died during the early posttransplant period (overall survival, 82.4%), and two required a second HCT for graft failure. Despite limitations due to cohort size and high pre-transplant morbidity in individual patients, HCT improved all major disease manifestations, including infections, inflammatory disease, and previously treatment-refractory EBV+ SMTs. No patient required immunoglobulin replacement after HCT, and no detrimental effects of mixed chimerism were noted. Allogeneic HCT is therefore a curative option for patients with CARMIL2 deficiency, which should be offered upon diagnosis.

Autor:innen und Institutionen

  • Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany.
  • Department of Pediatric and Adolescent Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Children's Hospital, University of Tübingen, Tübingen, Germany.
  • Pediatric Immunology and Allergy, Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey.
  • Radiology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Deptartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, USA.

ORCID-Profile: Johannes Raedler, Florian Gothe, Thomas Magg, Philipp Peters, Karen Helene Bronken Martinsen, Ursula Holzer, Ayca Kiykim, Ayse Kalyoncu Ucar, Roshini S Abraham, Hemalatha G Rangarajan, Adeeb NaserEddin, Polina Stepensky, Irina Zaidman, Ehud Even-Or, Joern-Sven Kuehl, Daniel Graefe, Venetia Bigley, Christo Tsilifis, Anders Fasth, Nizar Mahlaoui, Oliver Wegehaupt, Carsten Speckmann, Jean-Laurent Casanova, Christoph Klein, Bénédicte Neven, Vivien Béziat, Romain Lévy, Fabian Hauck

Förderung

  • LMU Munich
  • French National Research Agency
  • Institut National de la Santé et de la Recherche Médicale
  • Robert Debré association
  • German Society for Allergology and Clinical Immunology
  • Schlumberger Foundation
  • Else Kröner-Fresenius Stiftung
  • German Federal Ministry of Education and Research

Zitieren

APA

Raedler, J., Gothe, F., Magg, T., Peters, P., Bronken Martinsen, K. H., Holzer, U., Kiykim, A., Kalyoncu Ucar, A., Abraham, R. S., Rangarajan, H. G., NaserEddin, A., Stepensky, P., Zaidman, I., Even-Or, E., Kuehl, J. S., Graefe, D., Bigley, V., Tsilifis, C., Fasth, A., …, & Hauck, F. (2026). Allogeneic hematopoietic cell transplantation is curative in CARMIL2 deficiency. Journal of Human Immunity, 2(5). https://doi.org/10.70962/jhi.20250200

Vancouver

Raedler J, Gothe F, Magg T, Peters P, Bronken Martinsen KH, Holzer U, et al. Allogeneic hematopoietic cell transplantation is curative in CARMIL2 deficiency. Journal of Human Immunity. 2026;2(5). doi:10.70962/jhi.20250200

BibTeX
@article{Raedler2026,
  author = {Raedler, Johannes and Gothe, Florian and Magg, Thomas and Peters, Philipp and Bronken Martinsen, Karen Helene and Holzer, Ursula and Kiykim, Ayca and Kalyoncu Ucar, Ayse and Abraham, Roshini S and Rangarajan, Hemalatha G and NaserEddin, Adeeb and Stepensky, Polina and Zaidman, Irina and Even-Or, Ehud and Kuehl, Joern-Sven and Graefe, Daniel and Bigley, Venetia and Tsilifis, Christo and Fasth, Anders and Mahlaoui, Nizar and Wegehaupt, Oliver and Speckmann, Carsten and Casanova, Jean-Laurent and Klein, Christoph and Neven, Bénédicte and Béziat, Vivien and Lévy, Romain and Hauck, Fabian},
  title = {Allogeneic hematopoietic cell transplantation is curative in CARMIL2 deficiency},
  journal = {Journal of Human Immunity},
  year = {2026},
  volume = {2},
  number = {5},
  doi = {10.70962/jhi.20250200}
}
Kostenlos starten →